Mitochondria in rare immune diseases
Interferons (IFNs) represent the first line of defence against viruses, and upregulation of IFN signalling is the hallmark of a rare genetic group of diseases known as type I interferonopathies (T1IFNs). Nucleic acid metabolism and mitochondria seem to trigger IFN signalling and may constitute new therapeutic targets for T1IFNs. The EU-funded MitoFeron project will focus on a mitochondrial protein involved in enhanced IFN signalling observed in T1IFN patients and investigate its role in organelle homeostasis and IFN induction. The results will lead to a new clinical screening protocol for T1IFN patients and new targets for therapeutic intervention.
Call for proposal
See other projects for this call